The role of pharmacology in spinal cord protection during thoracic aortic reconstruction

Seminars in Thoracic and Cardiovascular Surgery

Volumn 15, Issue 4, 2003, Pages 365-377

  Reece, T Brett ^a,b   Kern, John A ^a,b   Tribble, Curtis G ^a,b   Cassada, David C ^a,b  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF TENNESSEE   (United States)

Author keywords

Paraplegia; Pharmacology; Spinal cord ischemia; Thoracic aorta; Vascular surgery

Indexed keywords

4 [3 [6 AMINO 9 (5 ETHYLCARBAMOYL 3,4 DIHYDROXYTETRAHYDRO 2 FURYL) 9H PURIN 2 YL] 2 PROPYNYL]CYCLOHEXANECARBOXYLIC ACID METHYL ESTER; ACTIVATED PROTEIN C; ADENOSINE; ADENOSINE A2A RECEPTOR AGONIST; ADENOSINE DERIVATIVE; ALLOPURINOL; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; BARBITURIC ACID DERIVATIVE; DEFEROXAMINE; DIAZOXIDE; ERYTHROPOIETIN; ILOPROST; MAGNESIUM SULFATE; MANNITOL; MEMANTINE; METHYLPREDNISOLONE; N METHYL DEXTRO ASPARTIC ACID; NALMEFENE; NALOXONE; OMEGA CONOTOXIN MVIIA; OPIATE ANTAGONIST; PHENYTOIN; PROSTACYCLIN; PROSTAGLANDIN E1; RILUZOLE; SUPEROXIDE DISMUTASE; TACROLIMUS; THIOPENTAL; TIRILAZAD; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AORTA SURGERY; HUMAN; NONHUMAN; POSTOPERATIVE COMPLICATION; REVIEW; RISK ASSESSMENT; SPINAL CORD INJURY; SPINAL CORD ISCHEMIA; THORACIC AORTA ANEURYSM;

EID: 0347136010     PISSN: 10430679     EISSN: None     Source Type: Journal    
DOI: 10.1053/S1043-0679(03)00088-1     Document Type: Review

References (87)

1. Mauney MC, Blackbourne LH, Langenburg SE, et al: Prevention of spinal cord injury after repair of the thoracic or thoracoabdominal aorta. Ann Thorac Surg 59: 245-252, 1995
2. Lemaire SA, Rice DC, Schmittling ZC, et al: Emergency surgery for thoracoabdominal aortic aneurysms with acute presentation. J Vasc Surg 35:1171-1178, 2002
3. Coselli JS, Conklin LD, LeMaire SA: Thoracoabdominal aortic aneurysm repair: Review and update of current strategies. Ann Thorac Surg 74:S1881-S1884, 2002
4. Coselli JS, LeMaire SA, Schmittling ZC, et al: Cerebrospinal fluid drainage in thoracoabdominal aortic surgery. Semin Vasc Surg 13:308-314, 2000
5. Golden MA, Donaldson MC, Whittemore AD, et al: Evolving experience with thoracoabdominal aortic aneurysm repair at a single institution. J Vasc Surg 13:792-796, 1991
6. Livesay JJ, Cooley DA, Ventemiglia RA, et al: Surgical experience in descending thoracic aneurysmectomy with and without adjuncts to avoid ischemia. Ann Thorac Surg 39:37-46, 1985
7. Cox GS, O'Hara PJ, Hertzer NR, et al: Thoracoabdominal aneurysm repair: A representative experience. J Vasc Surg 15:780-787, 1992
8. Svensson LG, Crawford ES, Hess KR, et al: Experience with 1509 patients undergoing thoracoabdominal aortic operations. J Vasc Surg 17:357-368, 1993
9. Krause GS, White BC, Aust SD, et al: Brain cell death following ischemia and reperfusion: A proposed biochemical sequence. Crit Care Med 16:714-726, 1988
10. Rothman S: Synaptic release of excitatory amino acid neurotransmitter mediates anoxic neuronal death. J Neurosci 4:1884-1891, 1984
11. Dumont RJ, Okonkwo DO, Verma S, et al: Acute spinal cord injury, part I: Pathophysiologic mechanisms. Clin Neuropharmacol 24:254-264, 2001
12. Gharagozloo F, Neville RF, Cox JL.: Spinal cord protection during surgical procedures on the descending thoracic and thoracoabdominal aorta: A critical overview. Semin Thorac Cardiovasc Surg 10:73-86, 1998
13. Svensson LG, Stewart RW, Cosgrove DM, et al: Intrathecal papaverine for the prevention of paraplegia after operation on the thoracic or thoracoabdominal aorta. J Thorac Cardiovasc Surg 96:823-829, 1988
14. Svensson LG, Grum DF, Bednarski M, et al: Appraisal of cerebrospinal fluid alterations during aortic surgery with intrathecal papaverine administration and cerebrospinal fluid drainage. J Vasc Surg 11:423-429, 1990
15. Marini CP, Grubbs PE, Toporoff B, et al: Effect of sodium nitroprusside on spinal cord perfusion and paraplegia during aortic cross-clamping. Ann Thorac Surg 47:379-383, 1989
16. Woloszyn TT, Marini CP, Coons MS, et al: Cerebrospinal fluid drainage does not counteract the negative effect of sodium nitroprusside on spinal cord perfusion pressure during aortic cross-clamping. Curr Surg 46:489-492, 1989
17. Nylander WA Jr, Plunkett RJ, Hammon JW, et al: Thiopental modification of ischemic spinal cord injury in the dog. Ann Thorac Surg 33:64-68, 1982
18. Kirshner DL, Kirshner RL, Heggeness LM, et al: Spinal cord ischemia: An evaluation of pharmacologic agents in minimizing paraplegia after aortic occlusion. J Vasc Surg 9:305-308, 1989
19. Yum SW, Faden AI: Comparison of the neuroprotective effects of the N-methyl-D-aspartate antagonist MK-801 and the opiate-receptor antagonist nalmefene in experimental spinal cord ischemia. Arch Neurol 47:277-281, 1990
20. Suzuki T, Okamoto Y, Sekikawa T, et al: Effects of GABAergic drugs on the recovery of reflex potentials after spinal cord ischemia in cats. Jpn J Pharmacol 68: 423-429, 1995
21. Joyce JA: Naloxone infusion combined with cerebrospinal fluid monitoring and drainage during thoracic aorta exploration: A case report. AANA J 64:480-484, 1996
22. Lang-Lazdunski L, Heurteaux C, Dupont H, et al: Prevention of ischemic spinal cord injury: Comparative effects of magnesium sulfate and riluzole. J Vasc Surg 32:179-189, 2000
23. Lips J, de Haan P, Bodewits P, et al: Neuroprotective effects of riluzole and ketamine during transient spinal cord ischemia in the rabbit. Anesthesiology 93:1303-1311, 2000
24. von Euler M, Li-Li M, Whittemore S, et al: No protective effect of the NMDA antagonist memantine in experimental spinal cord injuries. J Neurotrauma 14:53-61, 1997
25. Rimpilainen J, Pokela M, Kiviluoma K, et al: The N-methyl-D-aspartate antagonist memantine has no neuroprotective effect during hypothermic circulatory arrest: A study in the chronic porcine model. J Thorac Cardiovasc Surg 121:957-968, 2001
26. Ehrlich M, Knolle E, Ciovica R, et al: Memantine for prevention of spinal cord injury in a rabbit model. J Thorac Cardiovasc Surg 117:285-91, 1999
27. Simpson JI, Eide TR, Schiff GA, et al: Intrathecal magnesium sulfate protects the spinal cord from ischemic injury during thoracic aortic cross-clamping. Anesthesiology 81:1493-1499, 1994
28. Svensson LG, Von Ritter CM, Groeneveld HT, et al: Cross-clamping of the thoracic aorta. Influence of aortic shunts, laminectomy, papaverine, calcium channel blocker, allopurinol, and superoxide dismutase on spinal cord blood flow and paraplegia in baboons. Ann Surg 204:38-47, 1986
29. Burns LH, Jin Z, Bowersox SS: The neuroprotective effects of intrathecal administration of the selective N-type calcium channel blocker ziconotide in a rat model of spinal ischemia. J Vasc Surg 30:334-343, 1999
30. Owen AJ, Ijaz S, Miyashita H, et al: Zonisamide as a neuroprotective agent in an adult gerbil model of global forebrain ischemia: A histological, in vivo microdialysis and behavioral study. Brain Res 770:115-122, 1997
31. Graham SH, Chen J, Lan J, et al: Neuroprotective effects of a use-dependent blocker of voltage-dependent sodium channels, BW619C89, in rat middle cerebral artery occlusion. J Pharmacol Exp Ther 269:854-859, 1994
32. Gangemi JJ, Kern JA, Ross SD, et al: Retrograde perfusion with a sodium channel antagonist provides ischemic spinal cord protection. Ann Thorac Surg 69:1744-1748, 2000
33. Agee JM, Flanagan T, Blackbourne LH, et al: Reducing postischemic paraplegia using conjugated superoxide dismutase. Ann Thorac Surg 51:911-914, 1991
34. Granke K, Hollier LH, Zdrahal P, et al: Longitudinal study of cerebral spinal fluid drainage in polyethylene glycol-conjugated superoxide dismutase in paraplegia associated with thoracic aortic cross-clamping. J Vasc Surg 13:615-621, 1991
35. Qayumi AK, Janusz MT, Dorovini-Zis K, et al: Additive effect of allopurinol and deferoxamine in the prevention of spinal cord injury caused by aortic crossclamping. J Thorac Cardiovasc Surg 107:1203-1209, 1994
36. Qayumi AK, Janusz MT, Jamieson WR, et al: Pharmacologic interventions for prevention of spinal cord injury caused by aortic crossclamping. J Thorac Cardiovasc Surg 104:256-261, 1992
37. Reddy BR, Wynne J, Kloner RA, et al: Pretreatment with the iron chelator desferrioxamine fails to provide sustained protection against myocardial ischaemia-reperfusion injury. Cardiovasc Res 25:711-718, 1991
38. Reddy BR, Kloner RA, Przyklenk K: Early treatment with deferoxamine limits myocardial ischemic/reperfusion injury. Free Radic Biol Med; 7:45-52, 1989
39. Laschinger JC, Cunningham JN Jr, Cooper MM, et al: Prevention of ischemic spinal cord injury following aortic cross-clamping: Use of corticosteroids. Ann Thorac Surg 38:500-507, 1984
40. Tetik O, Islamoglu F, Yagdi T, et al: An intraaortic solution trial to prevent spinal cord injury in a rabbit model. Eur J Vasc & Endovasc Surg 22:175-9, 2001
41. Kanellopoulos GK, Kato H, Wu Y, et al: Neuronal cell death in the ischemic spinal cord: The effect of methyl-prednisolone. Ann Thorac Surg 64:1279-1285, 1997
42. Kouchoukos NT, Masetti P, Rokkas CK, et al: Safety and efficacy of hypothermic cardiopulmonary bypass and circulatory arrest for operations on the descending thoracic and thoracoabdominal aorta. Ann Thorac Surg 72:699-707, 2001
43. Francel PC, Long BA, Malik JM, et al: Limiting ischemic spinal cord injury using a free radical scavenger 21-aminosteroid and/or cerebrospinal fluid drainage. J Neurosurg 79:742-751, 1993
44. Fowl RJ, Patterson RB, Gewirtz RJ, et al: Protection against postischemic spinal cord injury using a new 21-aminosteroid. J Surg Res 48:597-600, 1990
45. Ohtake H, Urayama H, Katada S, et al: Prevention of spinal cord ischemia by selective intercostal arterial infusion of prostaglandin E1. J Vasc Surg 28:301-307, 1998
46. Grabitz K, Freye E, Prior E, et al: Does prostaglandin E1 and superoxide dismutase prevent ischaemic spinal cord injury after thoracic aortic cross-clamping? Eur J Vasc Surg 4:19-24, 1990
47. Katircioglu SF, Saritas Z, Yucel D, et al: Spinal cord protection with the use of prostacyclin during aortic occlusion. J Surg Res 65:77-81, 1996
48. Katircioglu SF, Ulus AT, Gokce P, et al: Iloprost protects the spinal cord during aortic cross-clamping in a canine model. J Cardiovasc Surg 41:89-93, 2000
49. Esmon CT: Protein C pathway in sepsis. Ann Med 34:598-605, 2000
50. Hirose K, Okajima K, Taoka Y, et al: Activated protein C reduces the ischemia/reperfusion-induced spinal cord injury in rats by inhibiting neutrophil activation. Ann Surg 232:272-280, 2000
51. Celik M, Gokmen N, Erbayraktar S, et al: Erythropoietin prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury. Proc Natl Acad Sci U S A 99:2258-2263, 2002
52. Lang-Lazdunski L, Heurteaux C, Dupont H, et al: The effects of FK506 on neurologic and histopathologic outcome after transient spinal cord ischemia induced by aortic cross-clamping in rats. Anesth Analg 92:1237-1244, 2001
53. Sullivan GW, Rieger JM, Scheld WM, et al: Cyclic AMP-dependent inhibition of human neutrophil oxidative activity by substituted 2-propynylcyclohexyl adenosine A(2A) receptor agonists. Br J Pharmacol 132:1017-1026, 2001
54. Linden J: Molecular approach to adenosine receptors: Receptor-mediated mechanisms of tissue protection. Annu Rev Pharmacol Toxicol 41:775-787, 2001
55. Sakurai M, Hayashi T, Abe K, et al: Delayed and selective motor neuron death after transient spinal cord ischemia: A role of apoptosis? J Thorac Cardiovasc Surg 115:1310-1315, 1998
56. Hasko G, Kuhel DG, Chen JF, et al: Adenosine inhibits IL-12 and TNF-α production via adenosine A2a receptor-dependent and independent mechanisms. FASEB J 14: 2065-2074, 2000
57. Burnstock G, Dobson JG, Liang BT, et al: Cardiovascular Biology of Purines. London, UK, Kluwer Academic Publishers, 1998
58. Seibel PS, Theodore P, Kron IL, et al: Regional adenosine attenuates postischemic spinal cord injury. J Vasc Surg 18:153-158, 1993
59. Herold JA, Kron IL, Langenburg SE, et al: Complete prevention of postischemic spinal cord injury by means of regional infusion with hypothermic saline and adenosine. J Thorac Cardiovasc Surg 107:536-541, 1994
60. Parrino PE, Kron IL, Ross SD, et al: Spinal cord protection during aortic cross-clamping using retrograde venous perfusion. Ann Thorac Surg 67:1589-1594, 1999
61. Parrino PE, Kron IL, Ross SD, et al: Retrograde venous perfusion with hypothermic saline and adenosine for protection of the ischemic spinal cord. J Vasc Surg 32:171-178, 2000
62. Ross SD, Kern JA, Gangemi JJ, et al: Hypothermic retrograde venous perfusion with adenosine cools the spinal cord and reduces the risk of paraplegia after thoracic aortic clamping. J Thorac Cardiovasc Surg 119:588-595, 2000
63. Peirce SM, Skalak TC, Rieger JM, et al: Selective A(2A) adenosine receptor activation reduces skin pressure ulcer formation and inflammation. Am J Physiol Heart Circ Physiol 281:H67-H74, 2001
64. Ross SD, Tribble CG, Linden J, et al: Selective adenosine-A2A activation reduces lung reperfusion injury following transplantation. J Heart Lung Transplant 18:994-1002, 1999
65. Fiser SM, Tribble CG, Kaza AK, et al: Adenosine A2A receptor activation decreases reperfusion injury associated with high-flow reperfusion. J Thorac Cardiovasc Surg 124:973-978, 2002
66. McPherson JA, Barringhaus KG, Bishop GG, et al: Adenosine A(2A) receptor stimulation reduces inflammation and neointimal growth in a murine carotid ligation model. Arterioscler Thromb Vasc Biol 21:791-796, 2001
67. Okusa MD, Linden J, Macdonald T, et al: Selective A2A adenosine receptor activation reduces ischemia-reperfusion injury in rat kidney. Am J Physiol 277:F404-F412, 1999
68. Okusa MD, Linden J, Huang L, et al: A(2A) adenosine receptor-mediated inhibition of renal injury and neutrophil adhesion. Am J Physiol Renal Physiol 279:F809-F818, 2000
69. Hogan CJ, Fang GD, Scheld WM, et al: Inhibiting the inflammatory response in joint sepsis. Arthroscopy 17: 311-315, 2001
70. Glover DK, Ruiz M, Takehana K, et al: Pharmacological stress myocardial perfusion imaging with the potent and selective A(2A) adenosine receptor agonists ATL193 and ATL146e administered by either intravenous infusion or bolus injection. Circulation 104:1181-1187, 2001
71. Riou LM, Ruiz M, Rieger JM, et al: Influence of propranolol, enalaprilat, verapamil, and caffeine on adenosine A(2A)-receptor-mediated coronary vasodilation. J Am Coll Cardiol 40:1687-1694, 2002
72. Cassada DC, Tribble CG, Kaza AK, et al: Adenosine analogue reduces spinal cord reperfusion injury in a time-dependent fashion. Surgery 130:230-235, 2001
73. Cassada DC, Gangemi JJ, Rieger JM, et al: Systemic adenosine A2A agonist ameliorates ischemic reperfusion injury in the rabbit spinal cord. Ann Thorac Surg 72:1245-1250, 2001
74. Cassada DC, Tribble CG, Laubach VE, et al: An adenosine A2A agonist, ATL-146e, reduces paralysis and apoptosis during rabbit spinal cord reperfusion. J Vasc Surg 34:482-488, 2001
75. Cassada DC, Tribble CG, Long SM, et al: Adenosine A2A agonist reduces paralysis after spinal cord ischemia: correlation with A2A receptor expression on motor neurons. Ann Thorac Surg 74:846-849, 2002
76. Cassada DC, Tribble CG, Long SM, et al: Adenosine A2A analogue ATL-146e reduces systemic tumor necrosing factor-alpha and spinal cord capillary platelet-endothelial cell adhesion molecule-1 expression after spinal cord ischemia. J Vasc Surg 35:994-998, 2002
77. Cassada DC, Tribble CG, Young JS, et al: Adenosine A2A analogue improves neurologic outcome after spinal cord trauma in the rabbit. J Trauma Injury Infect Crit Care 53:225-229, 2002
78. Munoz A, Nakazaki M, Goodman JC, et al: Ischemic preconditioning in the hippocampus of a knockout mouse lacking SUR1-based K(ATP) channels. Stroke 34:164-170, 2003
79. Loubani M, Galinanes M: Pharmacological and ischemic preconditioning of the human myocardium: mitoKATP channels are upstream and p38MAPK is downstream of PKC. BMC Physiol 2:10, 2002
80. Feng J, Li H, Rosenkranz ER: Diazoxide protects the rabbit heart following cardioplegic ischemia. Mol Cell Biochem 233:133-18, 2002
81. Wang QL, Wang G, Wang HM, et al: Effect of pretreatment with adenosine, diazoxide or ischemic preconditioning on ischemia-reperfusion injury in the limbs of rats. Di Yi Jun Yi Da Xue Xue Bao 22:617-619, 2002
82. Shake JG, Peck EA, Marban E, et al: Pharmacologically induced preconditioning with diazoxide: A novel approach to brain protection. Ann Thorac Surg 72:1849-1854, 2001
83. Ueno T, Chao ZL, Okazaki Y, et al: The impact of ischaemic preconditioning on spinal cord blood flow and paraplegia. Cardiovasc Surg 9:575-579, 2001
84. de Haan P, Vanicky I, Jacobs MJ, et al: Effect of ischemic pretreatment on heat shock protein 72, neurologic outcome, and histopathologic outcome in a rabbit model of spinal cord ischemia. J Thorac Carchovasc Surg 120:513-519, 2000
85. Abraham VS, Swain JA, Forgash AJ, et al: Ischemic preconditioning protects against paraplegia after transient aortic occlusion in the rat. Ann Thorac Surg 69:475-479, 2000
86. Zvara DA, Colonna DM, Deal DD, et al: Ischemic preconditioning reduces neurologic injury in a rat model of spinal cord ischemia. Ann Thorac Surg 68:874-880, 1999
87. Caparrelli DJ, Cattaneo SM II, Bethea BT, et al: Pharmacological preconditioning ameliorates neurological injury in a model of spinal cord ischemia. Ann Thorac Surg 74:838-844, 2002